Navigation Links
Shire to Introduce a New UK Listed Holding Company
Date:4/14/2008

ay Delisting of Shire ordinary shares from

the LSE, admission and listing of Shire

Limited ordinary shares, commencement of

dealings and crediting of Shire Limited

ordinary shares in uncertificated form to

CREST accounts

Within 10 Despatch of share certificates in respect

Business Days of Shire Limited ordinary shares in

after the Scheme certificated form.

Effective Date

This timetable is based on the Board's expectations and may be subject to change. Any changes to the timetable will be the subject of a further announcement. Key dates relevant to the holders of Shire ADSs may differ from those above and will be set out in full in the Circular.

Morgan Stanley & Co. International plc is acting as sponsor to Shire Limited's listing and as joint corporate broker. Deutsche Bank AG London is acting as joint corporate broker.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com

This announcement does
'/>"/>

SOURCE Shire PLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis
2. Shire plc: Long Term Incentive Plan
3. Shire plc: IFRS Results for the Year Ending December 31, 2007
4. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
5. Shire plc: Correction Re Website
6. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
7. Shire Engages Palio
8. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
11. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... Knowledgent , the data and analytics ... advanced analytics utilizing data lakes in the healthcare industry. , As the Internet of ... of data over the last few years as more entities become technology enabled through ...
(Date:9/1/2015)... ... 2015 , ... Industry leader iLab Solutions recently announced Gerard ... position, Gibbs will lead iLab’s business operations in the region, with an emphasis ... not only introducing iLab to potential partners but support and management of accounts ...
(Date:9/1/2015)... CA (PRWEB) , ... September 01, 2015 , ... ... and colleagues from University of California Los Angeles, Boston University School of Medicine, ... Prevention appears in PLOS One, the world’s first multidisciplinary Open Access journal. ...
(Date:9/1/2015)... Shire plc (LSE: SHP, NASDAQ: SHPG ) announces ... of Directors as a Non-Executive Director. Sara will also be ... the Shire Board. Both appointments will be effective as of ... President and Chief Executive Officer of Dun & Bradstreet, Inc. ... D&B, she helped drive the transformation of the company from ...
Breaking Biology Technology:New White Paper Explores Data Lake Opportunities in the Healthcare Industry 2iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 2iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 3Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 2Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 3Shire Appoints Sara Mathew to Board of Directors 2
... , PLYMOUTH MEETING, Pa., Oct. 30 /PRNewswire-Asia-FirstCall/ -- ... announced,it will participate in the following conferences: , , ... 2009 at the Waldorf=Astoria hotel in New ... at 3:20 pm ET on Tuesday, November 3, and meet with, ...
... drug, LX211 (LUVENIQ; oral voclosporin), may become the first ... uveitis, a group of serious eye conditions inevitably associated ... steroid use. Results of international Phase 2/3 clinical trials ... two podium presentations at the American Association of Ophthalmology ...
... 2009 Very tiny wires, called nanowires, made from such ... role as electrical or mechanical switches in the development ... require a deep understanding of how these and other ... their resultant strengths and weaknesses. How mechanical properties ...
Cached Biology Technology:BMP Sunstone Announces November Investor Conference Participation 2LX211 highlighted as potential disease modifying therapy for noninfectious uveitis 2LX211 highlighted as potential disease modifying therapy for noninfectious uveitis 3LANL Roadrunner simulates nanoscale material failure 2
(Date:8/19/2015)... HAUPPAUGE, N.Y. , Aug. 19, 2015 /PRNewswire/ ... announced that it has entered into a Definitive ... intellectual property, of iris authentication market leader EyeLock ... transaction, VOXX will have a controlling interest in ... is subject to completion of due diligence.  Expanding ...
(Date:8/12/2015)... Minn. , Aug. 12, 2015   MedNet ... supports the entire spectrum of clinical research, is proud ... , the company,s comprehensive SaaS-based eClinical technology platform, has ... during the first two quarters of 2015.   Q2 ... second largest quarters measured by contract value sold in ...
(Date:8/11/2015)... , August 11, 2015 Today, ZUK ... Already received as well as expected revenues in 2015 that relate ... FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a prominent smartphone manufacturer in ... ZUK selected FPC1 155 for ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5MedNet Solutions Experiences Explosive Corporate Growth 2FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
... More than 2,000 years after Archimedes found a way to ... mass in two different fluids, MIT scientists have used the ... to measure the density of a single cell. "Density ... Grover, a research associate in MIT,s Department of Biological Engineering. ...
... 21, 2011) -- The U.S. Department of Defense (DOD) ... of Engineering researchers for high-tech, specialized measuring equipment that ... engineering applications. The University of Arizona captured five of ... Engineering awardees are Armin Sorooshian of the Department of ...
... Richmond, Va. (June 20, 2011) Researchers at ... mechanisms in mitochondria that have implications for cancer as ... disease, heart disease and hypertension. This discovery has pioneered ... research ripe with possibilities of developing future gene therapies ...
Cached Biology News:How dense is a cell? 2How dense is a cell? 3UA engineering college lands national support for equipment used in unique research 2Discoveries in mitochondria open new field of cancer research 2
... sets a new standard for high performance ... new design in instrumentation, this easy-to-use benchtop ... The BD FACSAria instrument is the first ... flow cell. This new flow cell ...
Mouse monoclonal antibody raised against a partial recombinant COG2. NCBI Entrez Gene ID = COG2...
Mouse polyclonal antibody raised against a partial recombinant IFNA13. NCBI Entrez Gene ID = 3447...
Mouse monoclonal antibody raised against a full length recombinant LDB3. NCBI Entrez Gene ID = LDB3...
Biology Products: